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BMDC

:   bone marrow‐derived dendritic cells

CDN

:   cyclic dinucleotide

CMA

:   10‐carboxymethyl‐9‐acridanone

DMXAA

:   5,6‐dimethylxanthenone‐4‐acetic acid

DSB

:   double‐strand break

GM‐CSF

:   granulocyte macrophage colony‐stimulating factor

IFN

:   interferon

LMP

:   lysosomal membrane permeabilization

MAVS/IPS‐1

:   mitochondrial antiviral signaling protein/IFN‐β promoter stimulator‐1

MEF

:   mouse embryonic fibroblasts

MyD88

:   myeloid differentiation primary response gene 88

NAC

:   *N*‐acetyl‐[l]{.smallcaps}‐cysteine

PAMP

:   pathogen‐associated molecular pattern

PI

:   propidium iodide

PRR

:   pattern recognition receptor

qRT‐PCR

:   quantitative polymerase chain reaction with reverse transcription

RANTES

:   regulated on activation, normal T cell expressed and secreted

ROS

:   reactive oxygen species

SINCRO

:   *N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original

STING

:   stimulator of interferon genes

TLR

:   Toll‐like receptor

TNF‐α

:   tumor necrosis factor alpha

TRIF

:   TIR‐domain‐containing adapter‐inducing IFN‐β

1. INTRODUCTION {#cas13726-sec-0001}
===============

The development of effective strategies to activate the immune system for the treatment of cancer has become a major focus of research in cancer therapeutics. Indeed, remarkable progress has been made in cancer immunotherapies as typically exemplified by cancer‐targeting monoclonal antibody treatment, immune checkpoint blockade, cancer vaccine, and chimeric antigen receptor T‐cell therapy.[1](#cas13726-bib-0001){ref-type="ref"}, [2](#cas13726-bib-0002){ref-type="ref"} However, these therapies are not always effective, leaving a number of patients in need of alternatives. In this context, several major steps may be needed for the effective control of cancer by the immune system, and these include activation of innate immune responses necessary for activation of innate antitumor responses and priming of anticancer T‐cell responses.[3](#cas13726-bib-0003){ref-type="ref"}, [4](#cas13726-bib-0004){ref-type="ref"}

The innate immune system constitutes the first line of defense against invading pathogens. Recognition by one of several classes of PRR of PAMP results in immune activation.[5](#cas13726-bib-0005){ref-type="ref"} Among PRR, STING is a particular focus of attention in antitumor immune responses.[6](#cas13726-bib-0006){ref-type="ref"} STING is a PRR for CDN and also functions as an adaptor protein for multiple cytosolic receptors of double‐stranded DNA.[7](#cas13726-bib-0007){ref-type="ref"} The hallmark of STING pathway activation is the induction of type I IFN production,[8](#cas13726-bib-0008){ref-type="ref"}, [9](#cas13726-bib-0009){ref-type="ref"}, [10](#cas13726-bib-0010){ref-type="ref"} and there is good evidence that type I IFN exert antitumor activities.[11](#cas13726-bib-0011){ref-type="ref"} Therefore, the search for drugs that activate the STING‐type I IFN axis has been an attractive area for cancer immunotherapy.[7](#cas13726-bib-0007){ref-type="ref"}

To date, two synthetic small compounds, DMXAA and CMA, have been developed as STING agonists inhibiting tumor development.[12](#cas13726-bib-0012){ref-type="ref"}, [13](#cas13726-bib-0013){ref-type="ref"} Both compounds induce type I IFN production in antigen‐presenting cells and giving these compounds to mice suppresses tumor growth.[14](#cas13726-bib-0014){ref-type="ref"}, [15](#cas13726-bib-0015){ref-type="ref"} However, DMXAA and CMA function only in mouse cells, not in human cells.[12](#cas13726-bib-0012){ref-type="ref"}, [13](#cas13726-bib-0013){ref-type="ref"} In addition to these small compounds, ML RR‐S2, an analog of CDN, has been synthesized as another STING agonist.[14](#cas13726-bib-0014){ref-type="ref"}, [16](#cas13726-bib-0016){ref-type="ref"} Although ML RR‐S2 is effective both in mouse and in human cells and suppresses tumor growth in mice, type I IFN induction is restricted to antigen‐presenting cells and not to cancer cells.[14](#cas13726-bib-0014){ref-type="ref"} As type I IFN often exert antitumor activities by directly acting on cancer cells,[17](#cas13726-bib-0017){ref-type="ref"} it would be interesting to search drugs that induce type I IFN in cancer cells.

In the present study, we found that a synthetic small compound, SINCRO, activates the STING pathway in mouse and human cells, inducing IFN‐β gene expression. In addition, we also show that SINCRO treatment of cancer cells triggers cell death. Interestingly, SINCRO‐triggered cytotoxicity is independent of the STING pathway and conventional apoptosis‐inducing pathway, suggesting the dual function of SINCRO. We discuss the potential significance of the discovery and characterization of SINCRO for future drug development for cancer therapy.

2. MATERIALS AND METHODS {#cas13726-sec-0002}
========================

2.1. Reagents and cells {#cas13726-sec-0003}
-----------------------

SINCRO was kindly provided by Kowa Company, Ltd., Aichi, Japan. Mouse melanoma B16F1 cells, mouse colon carcinoma SL4 cells, human breast cancer HBC4 cells, human cervical carcinoma HeLa cells, mouse fibroblast NIH/3T3 cells, and HEK293T cells were maintained as described previously.[18](#cas13726-bib-0018){ref-type="ref"}, [19](#cas13726-bib-0019){ref-type="ref"} Mouse T‐lymphoma EL4 cells were obtained from RIKEN BioResource Research Center (Ibaraki, Japan) and maintained in DMEM (Nacalai Tesque, Kyoto, Japan) supplemented with 10% FBS (Hyclone, Logan, UT, USA). GM‐CSF‐induced BMDC, peritoneal macrophages, and MEF were prepared as described previously.[18](#cas13726-bib-0018){ref-type="ref"}, [20](#cas13726-bib-0020){ref-type="ref"}

2.2. Mice {#cas13726-sec-0004}
---------

C57BL/6 mice were purchased from CLEA Japan (Tokyo, Japan). *Tmem173* ^*−/−*^ mice (STING KO mice), *Myd88* ^*−/−*^ mice (MyD88 KO mice), and *Trif* ^*−/−*^ mice (TRIF KO mice) described previously were maintained as C57BL/6 background.[21](#cas13726-bib-0021){ref-type="ref"}, [22](#cas13726-bib-0022){ref-type="ref"} *Mavs* ^*−/−*^ mice (MAVS KO mice) were kindly provided by S. Akira (Osaka University). *Ifnar1* ^−/−^ mice (IFNAR1 KO mice) were described previously.[17](#cas13726-bib-0017){ref-type="ref"} All animal experiments were approved and carried out according to the guidelines of the animal research committee of the University of Tokyo.

2.3. Quantification of mRNA expression {#cas13726-sec-0005}
--------------------------------------

EL4 cells (5 × 10^5^ cells), BMDC (5 × 10^5^ cells), peritoneal macrophages (5 × 10^5^ cells), or other cancer cells (8 × 10^4^ cells) were treated with SINCRO (2.5, 5, or 10 μg/mL) or DMSO for 0, 4, 6, 8, 9, or 12 hours. In some experiments, the cells were stimulated with poly dA:dT (B‐DNA) (10 μg/mL) for 9 hours as described previously.[21](#cas13726-bib-0021){ref-type="ref"} Total RNA was extracted from the cells using RNAiso Plus (TaKaRa, Shiga, Japan) and reverse‐transcribed into cDNA with PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time) (TaKaRa) according to the manufacturer\'s instructions. qRT‐PCR was carried out as described previously.[23](#cas13726-bib-0023){ref-type="ref"} Expression levels of mouse and human mRNA were normalized to those of *Gapdh* and *GAPDH*, respectively. Primer sequences are as follows: *Ifnb* forward 5′‐ACGCCTGGATGGTGGTCCGA‐3′; *Ifnb* reverse 5′‐TGCCTGCAACCACCACTCATTCT‐3′; *Tnf* forward 5′‐TCATACCAGGAGAAAGTCAACCTC‐3′; *Tnf* reverse 5′‐GTATATGGGCTCATACCAGGGTTT‐3′; *Rantes* forward 5′‐ACGTCAAGGAGTATTTCTACAC‐3′; *Rantes* reverse 5′‐GATGTATTCTTGAACCCACT‐3′; *Sting* forward 5′‐AATAACTGCCGCCTCATTGT‐3′; *Sting* reverse 5′‐TCCTCCTTTTCTTCCTGACG‐3′; *Gapdh* forward 5′‐CTCATGACCACAGTCCATGC‐3′; *Gapdh* reverse 5′‐CACATTGGGGGTAGGAACAC‐3′; *IFNB* forward 5′‐AGCACTGGCTGGAATGAGAC‐3′; *IFNB* reverse 5′‐CTATGGTCCAGGCACAGTGA‐3′; *STING* forward 5′‐ GAGCAGGCCAAACTCTTCTG‐3′; *STING* reverse 5′‐ TGCCCACAGTAACCTCTTCC‐3′; *GAPDH* forward 5′‐CCTCCAAGGAGTAAGACCCC‐3′; *GAPDH* reverse 5′‐TGTGAGGAGGGGAGATTCAG‐3′.

2.4. Enzyme‐linked immunosorbent assay {#cas13726-sec-0006}
--------------------------------------

B16F1 cells (8 × 10^4^ cells) were cultured in the presence of SINCRO (2.5, 5, or 10 μg/mL), DMSO, or incubated with B‐DNA (10 μg/mL) as described above for 24 hours. IFN‐β concentration in the culture supernatant was measured by VeriKine Mouse IFN Beta ELISA Kit (PBL Assay Science, Piscataway, NJ, USA).

2.5. Optical characterization of SINCRO {#cas13726-sec-0007}
---------------------------------------

Absorbance spectrum of SINCRO (10, 25, 50, 100 or 200 μmol/L) or DMSO was measured using an ND‐1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Fluorescence emission spectrum of SINCRO (2 μmol/L) or DMSO with an excitation wavelength of 325 nm was obtained using a fluorescence spectrophotometer F‐7000 (HITACHI, Tokyo, Japan).

2.6. Immunoprecipitation assay {#cas13726-sec-0008}
------------------------------

cDNA encoding mouse STING tagged with human influenza hemagglutinin molecule corresponding to amino acids 98‐106 (HA‐STING) was cloned into pCXNII vector[24](#cas13726-bib-0024){ref-type="ref"} and expressed in HEK293T cells. Whole cell lysate was extracted using RIPA lysis buffer[20](#cas13726-bib-0020){ref-type="ref"} and was subjected to immunoprecipitation with anti‐HA antibody (12CA5; Roche, Basel, Switzerland) and Dynabeads Protein G (Life Technologies, Carlsbad, CA, USA). Then, HA‐STING‐bound beads were incubated with SINCRO (100 μg/mL) in PBS for 2 hours at 4°C and boiled in 15 μL PBS. Absorbance of 325 nm light was measured using an ND‐1000 spectrophotometer.

2.7. Confocal microscopy analysis {#cas13726-sec-0009}
---------------------------------

B16F1 cells (1.5 × 10^6^ cells) on glass‐bottom 35 mm dish (AGC TECNO GLASS, Shizuoka, Japan) were stimulated with SINCRO (10 μg/mL) for 3 hours and incubated with LysoTracker Deep Red (Molecular Probes, Eugene, OR, USA) according to the manufacturer\'s instructions. Confocal fluorescence images were obtained using a BZ‐X700 fluorescence microscope (KEYENCE, Osaka, Japan). For SINCRO visualization, 520 nm fluorescence emission by 325 nm excitation laser was detected.

2.8. Cell viability analysis {#cas13726-sec-0010}
----------------------------

EL4 cells (5 × 10^4^ cells), BMDC (7 × 10^4^ cells), or other cells (1 × 10^4^ cells) were incubated with SINCRO (2.5, 5, or 10 μg/mL) or DMSO for 40 hours and subsequently cultured in the presence of MTT; Dojindo, Kumamoto, Japan) (0.5 mg/mL) for 4 hours. After cells were lysed with DMSO, absorbance at 595 nm was measured. EC~50~ of SINCRO for cell killing was calculated using Image J (National Institutes of Health). For the inhibition of caspase activity, B16F1 cells were treated with Caspase Inhibitor Z‐VAD‐FMK (Promega, Madison, WI, USA) (20 or 40 μmol/L) or DMSO for 1 hour before SINCRO treatment. Inhibition of oxidative stress in B16F1 cells was carried out by treatment to the cells with NAC (Nacalai Tesque; 1 or 3 mmol/L) at the same time as SINCRO treatment.

2.9. Flow cytometry analysis {#cas13726-sec-0011}
----------------------------

B16F1 cells (8 × 10^4^ cells) were treated with SINCRO (10 μg/mL) for 0, 12, 24, or 36 hours and were stained with Annexin V and PI using an Annexin V‐FITC Apoptosis Detection Kit (Biovision, Milpitas, CA, USA). Proportion of Annexin V^+^ PI^+^ dead cells was analyzed using BD LSRII Fortessa (BD Biosciences, San Jose, CA, USA).

2.10. Immunoblot analysis {#cas13726-sec-0012}
-------------------------

B16F1 cells (2 × 10^6^ cells) were treated with SINCRO (10 μg/mL) or cisplatin (50 μmol/L) for 0, 6, or 12 hours. Whole cell lysates were prepared and immunoblot analysis was carried out as described previously.[20](#cas13726-bib-0020){ref-type="ref"} Antibodies for γH2AX (20E3), H2AX (D17A3), and cleaved caspase‐3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti‐LC3 antibody (8E10) and anti‐p62 polyclonal antibody were obtained from MBL (Aichi, Japan). Each protein level was quantified by analyzing its band intensity using Image J (National Institutes of Health).

2.11. In vivo tumor growth {#cas13726-sec-0013}
--------------------------

B16F1 cells (1 × 10^6^ cells) were inoculated s.c. into C57BL/6 or IFNAR1 KO mice. From day 9, SINCRO (10 μg) or DMSO in PBS was injected into the tumor every 2 days. Tumor volume was calculated as ab^2^/2 (where a represents longer axis of tumor and b represents shorter axis of tumor).

2.12. Statistical analysis {#cas13726-sec-0014}
--------------------------

Data were analyzed by two‐tailed, unpaired Student\'s *t* test. *P*‐value \<0.05 was considered significant.

3. RESULTS {#cas13726-sec-0015}
==========

3.1. SINCRO induces IFN‐β expression in cancer cells and immune cells {#cas13726-sec-0016}
---------------------------------------------------------------------

SINCRO is a small molecule compound (504.71 molecular weight) discovered for its potency in activating innate immune receptors (Figure [1](#cas13726-fig-0001){ref-type="fig"}A). SINCRO treatment of B16F1 mouse melanoma cells resulted in the induction of IFN‐β mRNA, a hallmark of innate immune activation, as well as TNF‐α and RANTES mRNA (Figures [1](#cas13726-fig-0001){ref-type="fig"}B and [S1](#cas13726-sup-0001){ref-type="supplementary-material"}). In addition, SINCRO‐induced IFN‐β mRNA and protein expression in B16F1 cells in a dose‐dependent way albeit the induction levels were much lower compared to the same cells stimulated with B‐form DNA (B‐DNA), a well‐characterized STING agonist[25](#cas13726-bib-0025){ref-type="ref"} (Figure [1](#cas13726-fig-0001){ref-type="fig"}C,D). Of note, SINCRO‐induced IFN‐β mRNA was observed in human cancer cell lines, although interestingly not in all examined cells (Figure [1](#cas13726-fig-0001){ref-type="fig"}E). Perhaps expectedly, SINCRO also induced IFN‐β mRNA in immune cells such as GM‐CSF‐induced BMDC and peritoneal macrophages (Figure [1](#cas13726-fig-0001){ref-type="fig"}F). Collectively, these observations indicate that SINCRO has IFN‐β‐inducing activity in both malignant and normal cells.

![*N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) induces interferon‐β (IFN‐β) expression in cancer cells and immune cells. A, Structural formula of SINCRO is shown. B, B16F1 cells (8 × 10^4^ cells) were treated with SINCRO (10 μg/mL) for the indicated time. IFN‐β mRNA expression was quantified by qRT‐PCR analysis. C,D, B16F1 cells (8 × 10^4^ cells) were cultured in the presence of SINCRO (2.5, 5 or 10 μg/mL), DMSO, or B‐DNA (10 μg/mL; B). C, IFN‐β mRNA expression was determined by qRT‐PCR analysis after incubation for 9 h. D, IFN‐β protein levels in the culture supernatant were measured by ELISA after 24 h treatment. E, EL4 cells (5 × 10^5^ cells), SL4 cells (8 × 10^4^ cells), HBC4 cells (8 × 10^4^ cells), or HeLa cells (8 × 10^4^ cells) were treated with SINCRO (10 μg/mL) for the indicated period. IFN‐β mRNA levels were quantified by qRT‐PCR analysis. F, Bone marrow‐derived dendritic cells (BMDC; 5 × 10^5^ cells) or peritoneal macrophages (5 × 10^5^ cells) were treated with SINCRO (10 μg/mL). IFN‐β mRNA levels at the indicated time points were quantified by qRT‐PCR analysis. Data are shown as mean ± SEM](CAS-109-2687-g001){#cas13726-fig-0001}

We next examined the mechanism(s) for how SINCRO regulates IFN‐β expression. As dead cell‐derived and exosomal nucleic acids have the potential to induce type I IFN,[10](#cas13726-bib-0010){ref-type="ref"}, [26](#cas13726-bib-0026){ref-type="ref"} we asked whether SINCRO induced the release of nucleic acids. To test this, we first stimulated B16F1 cells with SINCRO for 6 hours, removed the compound by washing, and then collected the medium from the cells incubated for another 6 hours. When the resulting conditioned medium was mixed with B16F1 cells, IFN‐β mRNA was not significantly induced in the B16F1 cells (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}A) whereas, in contrast, the mRNA was induced in the B16F1 cells used to prepare the conditioned media (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}B). Thus, we surmise that IFN‐β was not triggered by SINCRO‐mediated release of nucleic acids.

We next examined subcellular localization of SINCRO using confocal microscopy. First, the absorption and fluorescence properties of SINCRO were determined (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}C,D). In B16F1 cells treated with SINCRO, fluorescence associated with SINCRO was mainly detected within the endosome/lysosome of the cells based on colocalization with a LysoTracker cell dye (Molecular Probes) (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}E). Thus, these observations indicate that SINCRO is internalized into cells through the endocytosis pathway.

3.2. Involvement of the STING pathway for SINCRO‐mediated IFN‐β gene induction {#cas13726-sec-0017}
------------------------------------------------------------------------------

To further look for how SINCRO regulates IFN‐β, we considered the activation of innate immune receptors. TLR regulate expression of IFN‐β by signaling through MyD88 or TRIF adaptor molecules. In addition, cytosolic receptors such as MAVS/IPS‐1 and STING also induce expression of IFN‐β.[27](#cas13726-bib-0027){ref-type="ref"}, [28](#cas13726-bib-0028){ref-type="ref"} Bone marrow‐derived dendritic cells generated from mice deficient in either the common TLR adaptors or the cytosolic receptors were examined for IFN‐β expression by treatment with SINCRO. As shown in Figure [2](#cas13726-fig-0002){ref-type="fig"}, IFN‐β expression was abrogated in the BMDC lacking STING. In contrast, IFN‐β mRNA was observed to be normal in TRIF‐ or MAVS‐deficient BMDC, while marginally decreased in MyD88‐deficient cells as compared to BMDC derived from WT mice (Figure [2](#cas13726-fig-0002){ref-type="fig"}). Thus, these results indicate that SINCRO induces IFN‐β expression mainly through the STING pathway.

![*N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) induces STING‐dependent interferon (IFN)‐β expression. Bone marrow‐derived dendritic cells (BMDC; 5 × 10^5^ cells) prepared from WT,*Sting*‐deficient (STING KO), *Mavs*‐deficient (MAVS KO), *MyD88*‐deficient (MyD88 KO), or *Trif*‐deficient (TRIF KO) mice were stimulated with SINCRO (10 μg/mL) for the indicated times. IFN‐β mRNA expression was quantified by qRT‐PCR analysis. Data are shown as mean ± SEM. \**P* \< 0.05. \*\**P* \< 0.01. n.s., not significant. MAVS, mitochondrial antiviral signaling protein; MyD88, myeloid differentiation primary response gene 88; STING, stimulator of interferon genes; TRIF, TIR‐domain‐containing adapter‐inducing IFN‐β; WT, wild‐type](CAS-109-2687-g002){#cas13726-fig-0002}

DMXAA and CMA are compounds that directly bind to STING to induce antitumor activity.[12](#cas13726-bib-0012){ref-type="ref"}, [13](#cas13726-bib-0013){ref-type="ref"} We next asked whether SINCRO also interacts with STING. Mouse HA‐STING was prepared from the whole cell lysate of HEK293T cells expressing HA‐STING and incubated with SINCRO in vitro. Here, light absorption consistent with SINCRO (325 nm) was observed to be increased when HA‐STING was incubated with SINCRO (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}F, left). Expectedly, the increased absorption was observed only when SINCRO was present in the in vitro assay (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}F, right). As such, although further verification will be required, SINCRO may directly interact with STING for the activation of its downstream signaling pathway(s) (see [Discussion](#cas13726-sec-0021){ref-type="sec"}).

3.3. SINCRO induces cell death in cancer cells {#cas13726-sec-0018}
----------------------------------------------

In addition to immune cell activation, we also considered cytotoxic effects of SINCRO on cancer cells. SINCRO‐mediated cytotoxicity against B16F1 cells was analyzed by a MTT cell viability assay and Annexin V/PI staining. As shown in Figure [3](#cas13726-fig-0003){ref-type="fig"}A,B, SINCRO treatment decreased cell viability and increased Annexin V^+^ PI^+^ dead cell staining. Similar results were obtained across several mice and human cancer cell lines (Figure [3](#cas13726-fig-0003){ref-type="fig"}C). The cytocidal effect of SINCRO was observed to be most pronounced in the EL4 mouse lymphoma cells of those examined. In addition, SINCRO induced cell death in nontransformed cells such as BMDC, MEF, and NIH/3T3 cells; however, these cells are less sensitive to SINCRO compared to the above cancer cells (Figure [S3](#cas13726-sup-0001){ref-type="supplementary-material"}A). Although the cancer cells respond to SINCRO at low concentrations (ie, 2.5 or 5 μg/mL) (Figure [3](#cas13726-fig-0003){ref-type="fig"}), the nontransformed cells remain unresponsive (Figure [S3](#cas13726-sup-0001){ref-type="supplementary-material"}A). Indeed, EC~50~ of SINCRO for cell killing was almost 2‐fold lower in B16F1 cells compared to MEF (Figure [S3](#cas13726-sup-0001){ref-type="supplementary-material"}B).

![*N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) induces cell death in cancer cells. A, B16F1 cells (1 × 10^4^ cells) were cultured in the presence of SINCRO (2.5, 5 or 10 μg/mL) or DMSO for 40 h. Cell viability was evaluated by MTT assay. B, B16F1 cells (8 × 10^4^ cells) were stimulated with SINCRO (10 μg/mL) for the indicated time. Proportion of Annexin V^+^ PI ^+^ dead cells among whole cells was analyzed by flow cytometry. C, EL4 cells (5 × 10^4^ cells), SL4 cells (1 × 10^4^ cells), HBC4 cells (1 × 10^4^ cells), or HeLa cells (1 × 10^4^ cells) were treated with SINCRO (2.5, 5 or 10 μg/mL) or DMSO and cell viabilities were evaluated by MTT assay 40 h later. Data are shown as mean ± SEM](CAS-109-2687-g003){#cas13726-fig-0003}

3.4. SINCRO induces cell death in a STING‐ and caspase‐independent pathway {#cas13726-sec-0019}
--------------------------------------------------------------------------

To determine the mechanism of SINCRO‐mediated cell death, we first examined the involvement of the STING pathway using BMDC collected from STING‐deficient mice. Figure [4](#cas13726-fig-0004){ref-type="fig"}A shows that the viability of STING‐deficient BMDC decreased in the presence of SINCRO as observed in WT cells, suggesting that SINCRO triggers cell death distinctly from the STING pathway. In this context, it is interesting that SINCRO‐mediated cell death was observed in SL4 cells and HeLa cells, although IFN‐β mRNA induction by SINCRO was not observed in these cells (Figures [3](#cas13726-fig-0003){ref-type="fig"}C and [1](#cas13726-fig-0001){ref-type="fig"}E). Sensitivity to cell death by SL4 cells and HeLa cells was not due to their lack of functional STING as these cells expressed STING mRNA even at higher levels compared to B16F1 and HBC4 cells, respectively (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}A). Moreover, SL4 and HeLa cells responded to B‐DNA, a STING agonist, for the induction of IFN‐β mRNA[25](#cas13726-bib-0025){ref-type="ref"} (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}B). Thus, SINCRO exerts its cytocidal activity independently of the STING‐IFN pathway.

![*N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) triggers STING‐independent cell death without caspase‐3 activation. A, WT or *Sting*‐deficient (STING KO) mice‐derived bone marrow‐derived dendritic cells (BMDC) (7 × 10^4^ cells) were incubated with SINCRO (2.5, 5 or 10 μg/mL) or DMSO for 40 h. Cell viability was evaluated by MTT assay. B, B16F1 cells (2 × 10^6^ cells) were stimulated with SINCRO (10 μg/mL) or cisplatin (50 μmol/L; Cis) for the indicated times. Protein expression of γH2AX, H2AX, cleaved caspase‐3 and β‐actin was measured by immunoblot analysis. B, images for each protein are shown (left panel). Relative band intensities of γH2AX normalized with H2AX (middle panel) and cleaved caspase‐3 normalized with β‐actin (right panel) are shown. C, B16F1 cells (2 × 10^6^ cells) were treated with SINCRO (10 μg/mL) for the indicated period. Protein expression of LC3, p62, and β‐actin was detected by immunoblot analysis. Left panel shows band images for each protein. Relative band intensities of LC3‐II normalized with LC3‐I (middle panel) and p62 level normalized with β‐actin (right panel) are shown. Data are shown as mean ± SEM](CAS-109-2687-g004){#cas13726-fig-0004}

Many classical anticancer agents, such as cisplatin, induce apoptosis of cancer cells by causing DNA DSB and by activating effector caspases.[29](#cas13726-bib-0029){ref-type="ref"} We therefore next examined whether SINCRO induces DSB and caspase activation. Although cisplatin treatment of B16F1 cells increased the protein level of γH2AX, a well‐known indicator for DSB, and cleaved caspase‐3, a marker of apoptosis, SINCRO treatment did not affect levels of either (Figure [4](#cas13726-fig-0004){ref-type="fig"}B). In addition, a pan‐caspase inhibitor z‐VAD‐fmk treatment did not suppress SINCRO‐triggered cell death (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}C). These results indicate that SINCRO induces cell death through a mechanism independent of caspase‐mediated apoptotic pathways, including DSB‐induced apoptosis.

Notably, we found that SINCRO treatment of B16F1 cells increased p62 protein expression level, although not significantly affecting the level of an autophagosome marker LC3‐I/II (Figure [4](#cas13726-fig-0004){ref-type="fig"}C). p62 is known to be a substrate of autophagic protein degradation and to be upregulated in response to oxidative stress.[30](#cas13726-bib-0030){ref-type="ref"} In addition, ROS produced during oxidative stress induce caspase‐independent cell death.[31](#cas13726-bib-0031){ref-type="ref"}, [32](#cas13726-bib-0032){ref-type="ref"}, [33](#cas13726-bib-0033){ref-type="ref"}, [34](#cas13726-bib-0034){ref-type="ref"} Indeed, SINCRO‐induced B16F1 cell death was suppressed, albeit not completely, by treatment with NAC, a ROS scavenger (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}D). Thus, SINCRO induces cancer cell death through oxidative stress and other yet unknown mechanism(s), wherein STING and caspases are not involved.

3.5. Suppression of in vivo tumor growth by SINCRO {#cas13726-sec-0020}
--------------------------------------------------

The antitumor properties of SINCRO in vitro prompted us to examine whether SINCRO possesses antitumor activity in vivo. To test this, B16F1 cells were s.c. inoculated into C57BL/6 mice and then dosed with SINCRO intratumorally. As shown in Figure [5](#cas13726-fig-0005){ref-type="fig"}A, tumor volume became approximately 4‐fold smaller upon SINCRO treatment, indicating that SINCRO exerts antitumor activity in vivo. Interestingly, the decrease in tumor volume by SINCRO treatment was less when B16F1 cells were inoculated into mice deficient in one of the essential receptor components, IFNAR1, for type I IFN signaling (Figure [5](#cas13726-fig-0005){ref-type="fig"}B). These results suggest that both the type I IFN pathway and other pathway(s) in the recipient mice contribute to SINCRO‐mediated suppression of tumor growth.

![*N*‐{3‐\[(1,4′‐bipiperidin)‐1′‐yl\]propyl}‐6‐\[4‐(4‐methylpiperazin‐1‐yl)phenyl\]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) suppresses tumor growth in vivo. A, WT mice were s.c. inoculated with B16F1 cells (1 × 10^6^ cells) and then treated with SINCRO (10 μg) or vehicle intratumorally every 2 days from day 9. Tumor volume was measured every 2 d. B, *Ifnar1*‐deficient (IFNAR1 KO) mice were inoculated with B16F1 cells and treated with SINCRO or vehicle as (A). Data are shown as mean ± SEM. \**P* \< 0.05](CAS-109-2687-g005){#cas13726-fig-0005}

4. DISCUSSION {#cas13726-sec-0021}
=============

With recent advances in T‐cell--mediated cancer immunotherapies, much attention has been focused on ways to harness immune responses against cancers.[1](#cas13726-bib-0001){ref-type="ref"}, [2](#cas13726-bib-0002){ref-type="ref"} In the context of the regulation of antitumor immunity by innate immune receptors, STING has been shown to play critical roles in the activation of antitumor T‐cell responses.[8](#cas13726-bib-0008){ref-type="ref"}, [9](#cas13726-bib-0009){ref-type="ref"}, [10](#cas13726-bib-0010){ref-type="ref"} Based on these findings, agonists for STING, such as DMXAA, CMA and ML RR‐S2, have been developed and found to be effective in several tumor models.[14](#cas13726-bib-0014){ref-type="ref"}, [15](#cas13726-bib-0015){ref-type="ref"}, [16](#cas13726-bib-0016){ref-type="ref"} A limitation to advancement of some of these molecules for treatment of human malignancy is the lack of cross‐reactivity to humans.[12](#cas13726-bib-0012){ref-type="ref"}, [13](#cas13726-bib-0013){ref-type="ref"} In the present study, we report that SINCRO is a novel chemical compound that activates the STING pathway, inducing expression of IFN‐β and other cytokines (Figures [1](#cas13726-fig-0001){ref-type="fig"}B‐F and [S1](#cas13726-sup-0001){ref-type="supplementary-material"}). Thus, it is likely that SINCRO‐STING engagement activates both IRF and nuclear factor kappa B (NF‐κB) pathways.[7](#cas13726-bib-0007){ref-type="ref"} Unlike the above‐mentioned agonists, our results suggest that SINCRO can function in both mouse and human cells, although not all of the cells were responsive (Figure [1](#cas13726-fig-0001){ref-type="fig"}E,F).

We presented evidence that SINCRO activates the STING pathway for IFN‐β induction activity (Figure [2](#cas13726-fig-0002){ref-type="fig"}) and that SINCRO may directly bind to STING for its activation (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}F). However, as some cell lines show differential responses between SINCRO‐ and B‐DNA‐mediated induction of IFN‐β mRNA (Figures [1](#cas13726-fig-0001){ref-type="fig"}E, [S4](#cas13726-sup-0001){ref-type="supplementary-material"}A) suggests factors other than STING, presumably inactivated in these cells, are also required for SINCRO to activate this pathway.[25](#cas13726-bib-0025){ref-type="ref"} These observations raise the possibility that SINCRO interacts with other components upstream of the STING signaling pathway, such as cGAS (cyclic GMP‐AMP synthase), DDX41 (DEAD box protein 41), and IFI16 (IFN‐γ‐inducible protein 16) or as yet unknown molecules that lead to STING activation.[28](#cas13726-bib-0028){ref-type="ref"} SINCRO may therefore act on one or more of these molecules to activate the pathway and induce IFN‐β mRNA expression. Thus, further work will be required to clarify the exact mechanism for how SINCRO activates the STING pathway. It also remains to be examined whether STING activation by SINCRO promotes the expansion of tumor antigen‐specific T cells as do the other above‐mentioned STING agonists.

We also found that SINCRO exerts cytocidal activity on cancer cells. Perhaps expectedly, SINCRO showed a similar activity on untransformed cells such as BMDC particularly at high concentrations (Figure [S3](#cas13726-sup-0001){ref-type="supplementary-material"}A). The detailed mechanism for how SINCRO induces cell death remains unclear. STING deficiency in BMDC did not significantly affect SINCRO‐induced cell death (Figure [4](#cas13726-fig-0004){ref-type="fig"}A). Moreover, cell death was induced by SINCRO in SL4 cells and HeLa cells (Figure [3](#cas13726-fig-0003){ref-type="fig"}C), whereas IFN‐β induction by SINCRO was not observed (Figure [1](#cas13726-fig-0001){ref-type="fig"}E). These results indicate that SINCRO does not target the STING pathway to induce cell death. Moreover, as indicated in Figures [4](#cas13726-fig-0004){ref-type="fig"}B and [S4](#cas13726-sup-0001){ref-type="supplementary-material"}C, caspases were not substantially involved in SINCRO‐triggered cell death.

Instead, our results showed that the expression level of an autophagy substrate p62 was elevated by SINCRO treatment despite no downregulation of autophagy (Figure [4](#cas13726-fig-0004){ref-type="fig"}C). In this context, it has been reported that p62 expression levels are increased during oxidative stress,[30](#cas13726-bib-0030){ref-type="ref"} and oxidative stress is induced by LMP, the release of lysosomal components into the cytosol.[35](#cas13726-bib-0035){ref-type="ref"}, [36](#cas13726-bib-0036){ref-type="ref"} As SINCRO accumulates in the endosome/lysosome compartment (Figure [S2](#cas13726-sup-0001){ref-type="supplementary-material"}E), the aberrantly or prolonged SINCRO accumulation may cause LMP to increase oxidative stress in the cells. Thus, SINCRO stimulation possibly leads to the production of ROS to inactivate caspases and induce caspase‐independent cell death as reported previously.[31](#cas13726-bib-0031){ref-type="ref"}, [32](#cas13726-bib-0032){ref-type="ref"}, [33](#cas13726-bib-0033){ref-type="ref"}, [34](#cas13726-bib-0034){ref-type="ref"} Consistent with this notion, treatment with ROS scavenger NAC increased B16F1 cell viability upon SINCRO stimulation (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}D). As NAC treatment does not completely suppress SINCRO‐induced cell death, another mechanism(s) is clearly involved in the cytocidal activity of SINCRO (Figure [S4](#cas13726-sup-0001){ref-type="supplementary-material"}D). Further study is required to elaborate on the detailed mechanism of SINCRO‐induced cell death.

Finally, in our subcutaneous tumor growth model, SINCRO treatment actually suppressed tumor development (Figure [5](#cas13726-fig-0005){ref-type="fig"}A). We also suggested the effectiveness of IFN‐β‐inducing activity and cytocidal property of SINCRO on in vivo tumor suppression (Figure [5](#cas13726-fig-0005){ref-type="fig"}B). It has been known that immune checkpoint blockade therapy, which is notable for providing durable responses through reactivation of antitumor immune responses,[37](#cas13726-bib-0037){ref-type="ref"} shows more potent antitumor activity when combined with a STING agonist or cytotoxic drug treatment.[16](#cas13726-bib-0016){ref-type="ref"}, [38](#cas13726-bib-0038){ref-type="ref"}, [39](#cas13726-bib-0039){ref-type="ref"} In this context, activation of the IFN‐β pathway and induction of cancer cell death may enhance the therapeutic efficacy of immune checkpoint modulators.

In summary, herein, we have identified a novel synthetic small compound SINCRO that mediates antitumor activity by at least two mechanisms. One is through activation of STING‐mediated innate immune responses, whereas the other is through direct cytocidal activity on cancer cells. Despite the unique functions of SINCRO, it may have potential to cause adverse side‐effects due to its cytocidal activity in untransformed cells (Figure [S3](#cas13726-sup-0001){ref-type="supplementary-material"}A). Thus, our study may offer a new avenue of research to modify SINCRO structure so as to further potentiate its agonistic potential for STING, while enhancing cytocidal activity that is more selective to cancer cells.
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